Oral fingolimod (FTY720) for relapsing multiple sclerosis.

By L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, C. Polman, T. Haas, A. Korn, G. Karlsson, E. Radue. New England Journal of Medicine, 2006

949 citations recorded by the source corpus.

Subfields: Molecular Biology, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/0dfba7103b25473931b220a4b64de5ae3a720196

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Sarah Spiegel
2. Susan R. Schwab
3. S. Milstien
4. J. Cyster
5. J. Chun
6. M. Wymann
7. R. Schneiter
8. K. Takabe

In Pathology and Forensic Medicine

1. Roland Martin
2. C. Iadecola
3. J. Buckner

Citations in the corpus

• Lipid signalling in disease (2008, background): “FTY720 interferes with the exit of lymphocytes from lymph nodes, and therefore attenuates autoimmune disease (for example, multiple sclerosis”
• Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis (2010, background): “The first clinical evidence that fingolimod has therapeutic benefits in MS was provided in a 6-month, placebo-controlled Phase II trial involving 281 patients with relapsing M”
• Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis (2010, background): “Because fingolimod retains recently activated primary T cells and TCMs in lymphoid tissues, local immune responses that depend on these cells can be reduced or delayed, which may increase the risk of infections, including common viral infections such as colds and influenza.(31,71,90) However, memory”
• “Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic Targets (2008, background): “Furthermore, all phase 2 and 3 clinical trials of FTY720 described a transient but significant bradycardia after the first dose (Budde et al., 2002; Tedesco-Silva et al., 2005; Kappos et al., 2006).”
• Multiple sclerosis: a complicated picture of autoimmunity (2007, background): “, which is of interest, as an agonist for this receptor has been shown to reduce disease activity in multiple sclerosis in a clinical tria”
• Finding a way out: lymphocyte egress from lymphoid organs (2007, background): “FTY720 has shown promise in phase II clinical trials of multiple sclerosis, and it will be crucial to disentangle the effects on lymphocyte trafficking, the changes in activation of a range of immune cells, and the direct effects on endothelium and neuronal cell types that can also express S1P recep”
• THE ALLIANCE OF SPHINGOSINE-1-PHOSPHATE AND ITS RECEPTORS IN IMMUNITY (2008, result): “By contrast, treatment of patients with relapsing–remitting multiple sclerosis with considerably lower doses of FTY720 alone has proven to be beneficia”